Results 11 to 20 of about 14,856,428 (285)

Peripheral T cell lymphoma: clinical utility of romidepsin

open access: yesBlood and Lymphatic Cancer: Targets and Therapy, 2012
Jasmine Zain, Kathryn SaweyNYU Langone Medical Center, New York, USAIntroduction: Direct therapeutic targets, such as aberrant tumor cell genes and tumor cell markers, have been the focus of cancer treatment for more than 50 years.
Sawey K, Zain J
doaj   +1 more source

The function and origin of the CD4+ T cell in the classical Hodgkin lymphoma microenvironment [PDF]

open access: yes, 2012
PhDClassical Hodgkin lymphoma (CHL) is a germinal centre B cell malignancy where the bulk of the tumour comprises a non-clonal immune infiltrate enriched for CD4+ T cells.
Greaves, Paul
core   +4 more sources

Peripheral T-Cell Lymphomas of the T Follicular Helper Type: Clinical, Pathological, and Genetic Attributes

open access: yesHemato, 2022
Follicular helper T-cell (TFH) lymphomas comprise a unique group of T-cell lymphomas that represent neoplastic proliferations of follicular helper T-cells and share genetic, immunophenotypic, morphologic, and clinical features.
Karthik A. Ganapathi   +2 more
doaj   +1 more source

Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens. [PDF]

open access: yes, 2011
Peripheral T-cell lymphomas (PTCL) are generally less common and pursue a more aggressive clinical course than B-cell lymphomas, with the T-cell phenotype itself being a poor prognostic factor in adult non-Hodgkin lymphoma (NHL).
Graham P. Collins   +34 more
core   +2 more sources

Primary nodal peripheral T-cell lymphomas: diagnosis and therapeutic considerations

open access: yesRevista Brasileira de Hematologia e Hemoterapia, 2015
Nodal peripheral T-cell lymphomas are a rare group of neoplasms derived from post-thymic and activated T lymphocytes. A review of scientific articles listed in PubMed, Lilacs, and the Cochrane Library databases was performed using the term "peripheral T ...
Luis Alberto de Pádua Covas Lage   +6 more
doaj   +1 more source

Peripheral T-cell lymphoma

open access: yesBlood, 2011
AbstractPeripheral T-cell lymphomas (PTCLs) are a heterogeneous group of clinically aggressive diseases associated with poor outcome. Studies that focus specifically on PTCL are emerging, with the ultimate goal of improved understanding of disease biology and the development of more effective therapies.
Foss F. M.   +5 more
openaire   +4 more sources

Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma : endpoints of a spectrum of one disease? [PDF]

open access: yes, 2013
In contrast to the commonly indolent clinical behavior of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), T cell/histiocyte rich large B cell lymphoma (THRLBCL) is frequently diagnosed in advanced clinical stages and has a poor prognosis ...
Benjamin Rengstl   +41 more
core   +2 more sources

CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features

open access: yesHaematologica, 2013
Peripheral T-cell lymphoma, not otherwise specified is a heterogeneous group of aggressive neoplasms with indistinct borders. By gene expression profiling we previously reported unsupervised clusters of peripheral T-cell lymphomas, not otherwise ...
Bettina Bisig   +9 more
doaj   +1 more source

Peripheral T cell lymphoma in Asia [PDF]

open access: yesInternational Journal of Hematology, 2014
Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of mature T- and NK-cell neoplasms, the incidence of which is higher in Asian countries than in Western countries. Although its etiology is mainly unknown, several risk factors (such as genetic factors, abnormal immunity, environmental factors, and infectious causes) have been proposed.
Sanghui, Park, Young Hyeh, Ko
openaire   +2 more sources

Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma

open access: yes, 2014
Peripheral T-cell lymphoma (PTCL) encompasses a heterogeneous group of neoplasms with generally poor clinical outcome. Currently 50% of PTCL cases are not classifiable: PTCL-not otherwise specified (NOS).
Connors, J.M.   +37 more
core   +2 more sources

Home - About - Disclaimer - Privacy